Key Points
-
The insider executed a sale of 1,152 shares at $258.80 per share.
-
The transaction involved shares equal to 5% of the equity stake held directly by the insider prior to the filing.
-
This disposition was conducted through a direct ownership account.
Nadja West, Director at Tenet Healthcare(NYSE:THC), disposed of 1,152 shares of common stock on Sept. 2, 2026, as disclosed in a recent SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Transaction value | $298,138 |
| Shares sold | 1,152 |
| Post-transaction shares (directly held) | 23,653 |
| Post-transaction value | $6.1 million |
Transaction value based on SEC Form 4 weighted average sale price ($258.80); post-transaction value based on Sept. 2, 2026, market close ($258.53).
Key questions
- What was the magnitude of this transaction relative to the insider’s total direct equity position?
The sale involved 1,152 shares, representing 5% of the direct common stock holdings before the transaction, leaving the director with a remaining direct stake of 23,653 shares. - How does the current market value of the remaining holdings compare to the transaction proceeds?
The transaction generated approximately $298,138 in proceeds, while the insider’s remaining direct equity position is valued at $6.1 million based on the Sept. 2, 2026, market close price of $258.53. - What was the equity performance context leading up to this disposal?
At the time of execution on Sept. 2, 2026, shares were priced at $258.80, following a period in which the company delivered a 39% one-year total return. - How is the company’s operational structure defined?
Tenet Healthcare operates as a provider of health solutions across three primary divisions: Hospital Operations and Other, Ambulatory Care, and Conifer, including a network of acute care facilities that provide core hospital and diagnostic services.
Company Overview
| Metric | Value |
|---|---|
| Share Price (as of market close 2026-09-02) | $258.53 |
| Market Capitalization | $21.1 billion |
| Revenue (TTM) | $21.8 billion |
| Net Income (TTM) | $2.2 billion |
Company Snapshot
- Tenet Healthcare operates a comprehensive network of acute care facilities and ambulatory care centers that generate revenue through hospital operations, including emergency services, surgical procedures, diagnostic imaging, clinical laboratory services, and on-site pharmacy operations.
- The company operates through three primary divisions — Hospital Operations and Other, Ambulatory Care, and Conifer — which collectively deliver integrated healthcare services across inpatient, outpatient, and ancillary care settings.
- Tenet serves a diverse patient base, including insured individuals, government-sponsored program beneficiaries, and self-pay patients, positioning itself as a broad-based healthcare provider across multiple geographic markets.
Tenet Healthcare represents one of the largest healthcare facility operators in the United States, with 77,000 employees and a diversified service portfolio spanning acute care, ambulatory services, and healthcare management solutions. The company’s scale and multi-divisional structure provide operational leverage and diversified revenue streams across the healthcare continuum. With TTM revenue of $21.8 billion and net income of $2.2 billion, Tenet demonstrates significant profitability and market positioning within the medical care facilities sector.
What this transaction means for investors
On Sept. 2, West sold 1,152 shares in a transaction valued at approximately $298,138. Given the details of the transaction, this doesn’t appear to be more than a routine sale. While West sold over 1,100 shares, the insider still holds 23,653 shares, indicating continued alignment and conviction in the company’s future. In addition, as of this writing, the Tenet stock price has climbed 37.7% over the past year, outperforming the S&P 500‘s 14.8% return over the same period. Given the outperformance in Tenet’s stock price, it’s not unusual for an executive to consider selling shares to take some gains off the table. With the minimal number of shares sold and the strong stock price performance over the last year, this sale doesn’t appear to be a cause for concern for shareholders.
For what may be next for the Tenet stock price, analysts view the company favorably but appear to have cautious outlooks over the next year. Of the 24 who cover the company, 83% rate it a buy, while 17% rate it a hold. But from that group, the median one-year price target is $284. From today’s price of $261.99, that would represent a gain of 8.4%.
Should you buy stock in Tenet Healthcare right now?
Before you buy stock in Tenet Healthcare, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Tenet Healthcare wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have $387,158!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $1,365,749!*
Now, it’s worth noting Stock Advisor’s total average return is 932% — a market-crushing outperformance compared to 211% for the S&P 500. Don’t miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of September 19, 2026.
Jack Delaney has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.